Olgotrelvir

奥格特韦钠

Report date: 2026/01/29 13:37:33
NME

Base Information

Drug NameOlgotrelvir
Drug Alias NameOVYDSOOVYDSO (Sorrento Therapeutics)Olgotrelvir (Sorrento Therapeutics)Ovydso奥维宁 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitorsCathepsin L inhibitors
TargetsSARS-CoV-2-3C-like-proteinaseCathepsin L
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Pulmonary Disease, Chronic Obstructive
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryMainland China
Original Approved Date2025/10/28
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTexas A&M University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSorrento Therapeutics IncZhejiang Acea Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Pulmonary Disease, Chronic Obstructive
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksKEGG